What is Marinus Pharmaceuticals?
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of ganaxolone, a therapeutic agent designed to address epilepsy and neuropsychiatric disorders. Ganaxolone operates as a positive allosteric modulator of GABAA, targeting a well-established pathway in the brain known for its anti-seizure, anti-depressant, and anti-anxiety effects. The company is pursuing ganaxolone in multiple dosage forms, including intravenous, capsule, and liquid formulations, aiming to serve both adult and pediatric patient populations across acute and chronic care settings. Marinus has advanced its pivotal study in children with CDD, a rare form of epilepsy, and is also investigating ganaxolone for postpartum depression and refractory status epilepticus, positioning itself as a key player in neurological therapeutics.
How much funding has Marinus Pharmaceuticals raised?
Marinus Pharmaceuticals has raised a total of $360.2M across 11 funding rounds:
Series C
$21M
Stock Offering
$41.3M
Stock Offering
$27.7M
Stock Offering
$40.3M
Stock Offering
$45M
Stock Offering
$70M
Other Financing Round
$30M
Other Financing Round
$32.5M
Series C (2013): $21M featuring Sofinnova Ventures, Foundation Medicine, Domain Associates, Canaan Partners, and RusnanoMedInvest
Stock Issuance/Offering (2014): $41.3M backed by Undisclosed
Stock Issuance/Offering (2015): $27.7M with participation from Undisclosed
Stock Issuance/Offering (2017): $40.3M led by Bain Capital
Stock Issuance/Offering (2018): $45M supported by Undisclosed
Stock Issuance/Offering (2019): $70M featuring Undisclosed
Other Financing Round (2022): $30M backed by Oaktree Capital Management
Other Financing Round (2022): $32.5M with participation from Morgan Stanley and H.C. Wainwright & Co.
Key Investors in Marinus Pharmaceuticals
Sofinnova Ventures
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. They actively partner with ambitious entrepreneurs across the entire value chain of life sciences investments, from seed to later-stage, aiming to develop transformative innovations.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages. They have a strong track record of supporting biopharma and digital health startups.
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. They have a history of providing venture capital funding to numerous biopharmaceutical companies, leading to significant IPOs and M&A events.
What's next for Marinus Pharmaceuticals?
With a substantial funding history, Marinus Pharmaceuticals is poised for continued advancement in its clinical development programs. The recent major strategic investment signals strong investor confidence in the company's pipeline, particularly ganaxolone. This financial backing is expected to fuel ongoing research and development efforts, including the progression of pivotal studies and potential commercialization strategies. The company's focus on addressing unmet needs in epilepsy and neuropsychiatric disorders, coupled with its robust financing, positions it for significant growth and impact in the biopharmaceutical sector.
See full Marinus Pharmaceuticals company page
